LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Lista de Ações・Incyte Corp

Incyte Corp

Fechado

SetorSaúde

97.31 0.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

94.55

Máximo

97.83

Indicadores-chave
By Trading Economics
Rendimento	4.1M 303M
Vendas	-234M 1.3B
P/E Médio do Setor	13.445 49.701
EPS	1.81
Margem de lucro	23.834
Funcionários	2,844
EBITDA	-47M 367M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+12.15% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-31M 19B
Abertura anterior	97.13
Fecho anterior	97.31

Sentimento de Notícias

By Acuity

14%

86%

22 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

59.52 / 62.66 Suporte e Resistência

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de mai. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 de mai. de 2026, 22:52 UTC

Grandes Movimentos do Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 de mai. de 2026, 23:44 UTC

Ganhos

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 de mai. de 2026, 23:35 UTC

Conversa de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 de mai. de 2026, 23:15 UTC

Conversa de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 de mai. de 2026, 23:14 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 de mai. de 2026, 23:02 UTC

Conversa de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 22:27 UTC

Conversa de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 de mai. de 2026, 22:14 UTC

Conversa de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 de mai. de 2026, 22:10 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 de mai. de 2026, 22:00 UTC

Ganhos

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 de mai. de 2026, 21:38 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 de mai. de 2026, 21:27 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 de mai. de 2026, 21:20 UTC

Ganhos

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 de mai. de 2026, 21:19 UTC

Ganhos

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 de mai. de 2026, 21:18 UTC

Ganhos

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 de mai. de 2026, 21:16 UTC

Ganhos

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

12.15% parte superior

Previsão para 12 meses

Média 108.88 USD 12.15%

Máximo 135 USD

Mínimo 75 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para Incyte Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

22 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation